Lifecore Biomedical, Inc. De (LFCR) EBIT Margin (2010 - 2025)

Lifecore Biomedical has reported EBIT Margin for 16 years, with the latest figure at 7.44% in Q2 2025.

• On a quarterly basis, EBIT Margin rose 177.0% year-over-year to 7.44% in Q2 2025; TTM through May 2025 was 10.51%, a 362.0% decrease from a year earlier, with the FY2025 full-year figure at 13.38%, down 649.0% from the prior year.
• EBIT Margin was 7.44% for Q2 2025 at Lifecore Biomedical, up from 25.68% in the prior quarter.
• The five-year high for EBIT Margin was 14.41% in Q4 2021, with the low at 46.89% in Q3 2024.
• Average EBIT Margin over 5 years is 13.75%, with a median of 14.28% recorded in 2021.
• The sharpest annual moves came in 2021 and 2022: EBIT Margin soared 2784 bps in 2021, then sank 3889 bps in 2022.
• Over 5 years, EBIT Margin stood at 14.41% in 2021, then slumped by 270 bps to 24.48% in 2022, then surged by 80 bps to 4.92% in 2023, then fell by 22 bps to 6.02% in 2024, then soared by 224 bps to 7.44% in 2025.
• The last three EBIT Margin figures came in at 7.44% (Q2 2025), 25.68% (Q1 2025), and 6.02% (Q4 2024), per Business Quant data.